Sign Up to like & get
recommendations!
0
Published in 2022 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2022.4338
Abstract: (842 pg/mL and 1,356 pg/mL, respectively). The patient showed good compliance with 4 mg/day baricitinib treatment, without any relapse or adverse events. The EASI score remained 5 until 52 weeks, and DLQI, P-NRS, and ADCT…
read more here.
Keywords:
non type;
agalactiae induced;
jak inhibitors;
type cytokines ... See more keywords